Brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report $51.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest sales estimate coming in at $53.00 million and the lowest estimate coming in at $49.70 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The company is scheduled to report its next earnings results on Wednesday, February 13th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $191.47 million for the current year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts expect that the company will post sales of $248.30 million, with estimates ranging from $229.00 million to $277.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up 18.9% compared to the same quarter last year.
VNDA has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “hold” rating and issued a $26.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 3rd. Oppenheimer set a $29.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 8th. Stifel Nicolaus set a $31.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 8th. Citigroup increased their target price on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and an average target price of $28.43.
Hedge funds and other institutional investors have recently modified their holdings of the business. United Services Automobile Association acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at approximately $211,000. Trexquant Investment LP acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Hartford Investment Management Co. acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $214,000. Meeder Asset Management Inc. grew its stake in Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 7,102 shares in the last quarter. Finally, NumerixS Investment Technologies Inc grew its stake in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 5,700 shares in the last quarter.
VNDA stock opened at $25.04 on Monday. Vanda Pharmaceuticals has a 1 year low of $13.10 and a 1 year high of $25.48. The stock has a market capitalization of $1.31 billion, a PE ratio of -71.54, a P/E/G ratio of 3.41 and a beta of 1.06.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Recommended Story: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.